Lupin partners with Honeywell to develop eco-friendly inhalers 

Lupin announced on Tuesday that it will incorporate Honeywell’s Solstice Air propellant in its next-generation respiratory inhalers, becoming the first Indian pharmaceutical company to use this technology at scale.

The partnership aims to transform respiratory care for asthma and chronic obstructive pulmonary disease (COPD) patients while significantly reducing environmental impact. Honeywell’s HFO-1234ze cGMP propellant can decrease greenhouse gas emissions by up to 99.9 per cent compared to traditional hydrofluorocarbon-based propellants in pressurised metered-dose inhalers.

“Lupin’s partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future,” said Vinita Gupta, CEO of Lupin.

Jeff Dormo, a president in Honeywell’s Energy and Sustainability Solutions business, emphasised that Solstice Air will help ensure Lupin’s devices provide effective treatment while reducing harmful greenhouse gas emissions.

Negotiation ongoing

The terms of the deal remain subject to negotiation and execution of definitive agreements between both companies.

Lupin operates globally with products distributed in over 100 markets, maintaining a strong presence in India and the US across multiple therapy areas including respiratory, cardiovascular and anti-diabetic treatments. The company has 15 manufacturing sites and seven research centres worldwide, with more than 23,000 employees.

The shares of Lupin closed at ₹1,969.50, down ₹60.10 or 2.96 per cent on the NSE.

Published on May 20, 2025